Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.

Revenue
+19.2%
EPS
+64.1%
Free cash flow
−29.8%
Total debt
−5.19%

Quarter to September 2026, against a year earlier

145.49 10.63 −6.81%
Market cap
$10.8B
P/E
25.2×
Fwd P/E
24.4×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a

Insulet Corporation (PODD) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by products and services, and margins
U.S. 1,920 70.89%
International 754 27.85%
Drug Delivery 34 1.26%
Gross margin 71.63%
Operating margin 17.50%
Pre-tax margin 12.54%

Revenue by product or service $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014
U.S. 1,920 1,509 1,251 885 652 527 420 324 272 230 190 176
International 754 523 410 363 360 308 253 172 120 72 40 50
Drug Delivery 34 39 36 58 87 70 65 68 72 65 34 5
Total Omnipod products 2,674 2,033 1,661 1,248 1,011 835 674 496 392 — — —
Revenue 2,708 2,072 1,697 1,305 1,099 904 738 564 464 367 264 231

Gross profit by product or service $m, and margin

Revenue by region $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014
U.S. 1,954 1,548 1,287 942 739 596 485 392 344 295 224 181
International 754 523 410 363 360 308 253 172 120 72 40 50
Revenue 2,708 2,072 1,697 1,305 1,099 904 738 564 464 367 264 231

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.